OPAT

The standing claim

OPAT exists to deliver equivalent clinical outcomes with the patient at home rather than in a bed. But the sharper, more recent insight is that the greatest value often comes one step earlier: not giving intravenous antibiotics at all where oral treatment is non-inferior. “Good” in this domain is therefore two things at once — a well-governed service for those who genuinely need IV, and the discipline to right-size who that is.

Where practice stands

The model is unusually well-codified. The BSAC/BIA Good Practice Recommendations — the most widely adopted OPAT service standard internationally — specify a minimum four-role multidisciplinary team (a treating clinician, an infection specialist, a specialist nurse and an antimicrobial pharmacist), documented patient-selection criteria, at-least-weekly monitoring while on IV antimicrobials, and formal governance (Chapman et al., 2012; updated 2026). NHS England’s 2025 OPAT guidance asks services for MDT assessment within 24 hours of referral, a treatment plan within 48 hours, weekly MDT review and 24-hour access to advice; NHS England estimates OPAT is 23–56% cheaper than equivalent inpatient care and that services avoided on the order of 280,000 bed-days nationally in 2020–21 (figures attributable to NHS England). The knowledge is not the constraint; provision is uneven across systems — a capacity and equity gap, not an epistemic one.

What good looks like

Three things define it, on the evidence:

1. The governance standard. The BSAC recommendations and the IDSA 2018 guideline converge: a defined MDT, mandatory infection-specialist review before OPAT, structured patient selection, and serial laboratory monitoring (IDSA makes infection-specialist review and serial monitoring strong recommendations).

2. Right-sizing IV — the OVIVA pivot. According to PubMed, the OVIVA trial (Li et al., 2019 — a 26-NHS-hospital randomised non-inferiority trial, n=1,054) found oral antibiotics non-inferior to intravenous for bone and joint infection (treatment failure ~13% oral vs ~15% IV; non-inferiority met), with far fewer IV-catheter complications and around £2,740 saved per patient (DOI). So best practice increasingly means avoiding IV where oral suffices — with UKHSA’s national IV-to-oral switch (IVOS) criteria and NICE NG15’s 48–72-hour review of every IV antimicrobial as the upstream filter that decides who reaches OPAT at all.

3. Agent selection for the patients who do need IV. Choosing once-daily, OPAT-friendly agents matters: a meta-analysis found ceftriaxone non-inferior to standard care for meticillin-sensitive Staphylococcus aureus bloodstream infection — except infective endocarditis (Alsowaida et al., 2022), a precise boundary that good services respect.

The exemplar is the UK itself, chosen on outcome data rather than reputation: OVIVA — the landmark that reframed global practice — ran on NHS infrastructure, and the BSAC standard is the international convergence point (its 2026 update is co-authored with US and Australian specialists). Australia’s mature Hospital-in-the-Home programmes are the credible peer for scale; the US model is clinically mature but shaped by a different reimbursement structure, reducing transferability to a tax-funded system.

Through the lenses

Through the VAT lens, an intravenous line is often exchange-value activity — visible, billable, reassuring — that can be avoided without loss of cure; the use value is the cure achieved with days spent at home and fewer line complications. This is McGilchrist’s caution in miniature: do not mistake the intervention (the line, the activity) for the thing it was meant to serve (the patient cured). Cross-domain, OPAT and oral-switch are admission-avoidance levers that connect directly to acute frailty (D01) and depend on community nursing capacity.

Confidence and limits

OVIVA is high-certainty randomised evidence — but specific to bone and joint infection; it should not be over-generalised to all infections (endocarditis behaves differently). The BSAC and IDSA documents are consensus/guideline standards; many of their recommendations rest on low-quality evidence despite strong wording, which they state openly. The NHS England cost and bed-day figures are service estimates, not trial outcomes. And the central limit is structural: the model is far more complete on paper than in uniform delivery — the capacity gap is real.

What we are watching

Uptake of the IVOS criteria (how much IV is safely avoided upstream); the equity of OPAT provision across systems; and whether the oral-switch evidence base extends robustly to infection types beyond bone and joint.